Objectives: Trazodone and nefazodone are phenylpiperazine antidepressants. Currently, there are no adequate, well-controlled studies on the fetal safety of these drugs. Our primary objective was to determine whether the use of trazodone or nefazodone during pregnancy is associated with an increased risk for major malformations. Secondary outcomes of interest included rates of spontaneous and therapeutic abortions, rates of premature labour, and birth weight.
T razodone is a phenylpiperazine antidepressant. At high dosages in some animal species, it is fetal-toxic and teratogenic. There have been no postmarketing reports of human fetal abnormalities associated with this drug (1) . A surveillance study of Michigan Medicaid recipients found that, of 100 newborns exposed to trazodone during the first trimester, 1 had major malformation (F Rosa, personal communication, 1993) .
Nefazodone is a phenylpiperazine antidepressant directly related to trazodone. At high dosages in some animal species, it was fetal-toxic but not teratogenic. There have been no postmarketing reports of human fetal abnormalities associated with this drug (2) . A manufacturer's report of 84 cases of exposure in pregnancy listed 48 outcomes, including 2 babies with renal abnormalities. In these 2 cases, there were no details regarding the time of exposure during pregnancy. In 38 of the pregnancies, the mother took the drug in the first trimester (Bristol-Myers Squibb, personal communication, 2001). A literature search did not uncover any human prospective controlled studies on the use of these drugs during pregnancy.
A significant number of women of child-bearing age suffer from depression. Coupled with the fact that at least 50% of pregnancies are unplanned (3), it is likely that some women will use trazodone or nefazodone in early pregnancy. We have found that some women have chosen to abort a wanted pregnancy because they lack information on the safety of a particular drug (4) . In another study we showed that, owing to misinformation coupled with fear, several women elected to abruptly discontinue needed antidepressants after pregnancy was diagnosed (5) . This fear of taking drugs during pregnancy persists, despite the fact that several antidepressants have not been found to be harmful. These include tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) (6) (7) (8) (9) (10) .
A British study documented that research on maternal depression during pregnancy has been relatively neglected in favour of studies of postnatal depression, even though maternal depression is more prevalent, and approximately 25% of postpartum depressions actually began during pregnancy (11) . The American Psychiatric Association Committee on Research on Psychiatric Treatments identified treatment of major depression during pregnancy as a priority clinicalmanagement area. Based on this recommendation, a position paper was published on risk-benefit decision making for treatment of depression during pregnancy. The authors concluded that no evidence existed to implicate antidepressants as a cause of harm to an unborn baby and that pregnant women should be treated, provided that the benefits and possible risks are well explained to them (12) . Another recent study found that untreated depression during pregnancy can have deleterious effects on peripartum and neonatal outcomes, including more caesarean sections and more admissions to neonatal intensive care units (13) .
With this in mind, and given the probability that more women will be treated pharmacologically for depression during pregnancy, it is of the utmost importance to study the fetal safety of all antidepressants, so that women can choose an antidepressant that is both safe and effective.
Our primary objective was to ascertain whether trazodone or nefazodone increased the baseline risk of 1% to 3% for major malformations. Secondary objectives included possible effects on spontaneous and therapeutic abortions, gestational age, and birth weight.
Patients and Methods
The Motherisk Program and the other participating centres are counselling services for pregnant and lactating women and their health professionals. These centres provide information on the safety or risk of drugs, chemicals, radiation treatment, and infectious diseases. For this study, we attempted to follow up all women who had called each service requesting information about the safety of trazodone or nefazodone during the first trimester of their pregnancy and to ascertain the outcome of their pregnancies.
Upon successful contact, we used a structured questionnaire to obtain a history of drug exposure and pregnancy outcome, along with other endpoints of interest. Exposure history included the medical indication for drug use, dosage, frequency of administration, and timing of exposure, as well as maternal demographics and obstetrical history. At follow-up, we questioned women regarding the course of their pregnancy, the health of their child, and the specific details of their exposure to trazodone or nefazodone and any concomitant drugs or other exposures. Outcomes were confirmed by a letter asking the child's primary care physician to corroborate the mother's information.
The primary outcome of interest was the incidence of major malformations, which were defined as the presence of any anomaly with an adverse effect on either the function or the social acceptability of the child (14) . Secondary outcomes included the rates of spontaneous or therapeutic abortions, livebirths and stillbirths, gestational age at birth, and birth weight. Exposure was defined as occurring during organogenesis if the drug was consumed between the fourth and fourteenth week of gestation.
We used 2 groups of women to compare the endpoints, with data collected in the same fashion. These groups were 1) disease-matched women suffering from depression but taking other nonteratogenic antidepressants and 2) women exposed to other nonteratogenic drugs (specifically, sumatriptin [15] , dextromethorphan [16] , diclectin [17] , and clarithromycin [18] ). They were also compared for age, smoking, and alcohol use and matched for time of call, because reported spontaneous abortions rates are probably higher when women call earlier in pregnancy. Most women were followed up between 4 and 6 months after their expected confinement date. Outcomes of interest were compared among the study and comparison groups with the chi-square, Fisher's exact, and analysis of variance (ANOVA) statistical tests.
We received oral consent from each participant after the study was fully explained over the telephone. Our hospital research ethics board approved the study.
Results
We were able to ascertain the outcomes of 147 pregnancies from 5 different centres located in Toronto, Ontario; Farmington, Connecticut; Milan, Italy; London, Ontario; and Detroit, Michigan. All the women used the drugs during the first trimester, with 52 (35%) using the drug throughout their pregnancies. There were no significant differences in the maternal characteristics of the exposed and comparison groups, with the exception that the trazodone or nefazodone group combined with the other antidepressants group had more smokers: 21% vs 8.2% (P = 0.015). However, most of these women had reduced the number of cigarettes smoked during their pregnancies, with only 4 women in the antidepressant groups smoking in excess of 20 cigarettes daily. There were no differences in any outcome measures for smokers, compared with nonsmokers, including the rates of spontaneous abortions and mean birth weights.
There were 121 (82.4%) live births, 20 (13:6%) spontaneous abortions, and 6 (4%) therapeutic abortions. Of the live births, there were 2 (1.6%) major malformations. The mean birth weight was 3288 g (SD 708). Among the 3 groups, pregnancy outcome (including rates of preterm delivery) did not differ, except that there were more spontaneous abortions in both antidepressant groups. However, this difference did not reach statistical significance (Table 1). There were 2 major malformations in the exposed group; in the other antidepressant group, there were 3 major malformations. There were 4 major malformations in the nonteratogen group (Table 2) .
Discussion
To our knowledge, this is the first prospective controlled study examining the risk or safety of trazodone or nefazodone use during pregnancy with all women exposed during the first trimester and 35% exposed throughout the pregnancy. However, it must be noted that this study did not attempt to evaluate potential neurobehavioural effects of these drugs.
The only difference among the groups was in the rate of spontaneous abortions, which was higher in both the exposed group and in the other antidepressant group (13.4% and 11.2%, respectively, compared with 8% in the nonteratogen group) ( Table 1) . To date, this increase in the rate of spontaneous abortion has been reported in 3 studies from our group. In our study of fluoxetine, the rate was 13.5% in the exposed group, 12% in the tricyclic group, and 7% in the Motherisk general population group (6) . With the newer SSRIs, the rate in the exposed group, compared with the general Motherisk population, was 12% vs 7% (7) . Finally in our most recent antidepressant study (of venlafaxine) there was a 12% spontaneous abortion rate in the antidepressant groups, compared with 7% in the Motherisk general population group (10) . A European teratology information group also published a study on pregnancy outcomes for 6 different antidepressants. In that cohort, the rates of spontaneous abortions ranged from 10.6% to 13.2%; however, there was no comparison group (19) . In addition, Eli Lilly has published a report of their fluoxetine pregnancy registry comprising 796 spontaneous reports of pregnancy outcomes, including 110 (13.8%) spontaneous abortions (20) . Despite the reports of higher spontaneous abortion rates, it must be noted that the results did not reach statistical significance in any of these studies. Further, they were in the expected range of up to 15% in the general population.
The results continue to raise the question whether there may be a possible causative association between depression and an increase in spontaneous abortion rates-a reason for our selecting as one of our comparison groups a disease-matched group of women also suffering from depression. It is also possible that, in some cases, a woman who is treated for depression may decide to terminate her pregnancy but choose to report it as a miscarriage, owing to guilt about her decision.
Women who have been diagnosed with depression prior to becoming pregnant should weigh the benefits and risks carefully with their physician before deciding whether to continue or discontinue an antidepressant during pregnancy. If they do decide to discontinue, the medication should be tapered off slowly to avoid abrupt discontinuation syndrome. Increasing evidenced-based information should reassure women and their health professionals that the benefits of taking an antidepressant in pregnancy can largely outweigh any unproven risks. In fact, failure to treat depression during pregnancy can have significant negative ramifications for both the mother and child. For example, a mother with severe depression may not be able to carry out her maternal duties in an optimal fashion and could have difficulty bonding with her child (21, 22) . A recent study also found that depression and anxiety in early pregnancy are associated with a risk for subsequent preeclampsia (23) .
Although several recent case reports have documented hepatotoxicity associated with the use of nefazodone (24) , this adverse effect was not reported by any of the women in our study.
A limitation of this study is the sample size, which is small for statistical purposes, and has only an 80% power to detect a fourfold increase in the rate of malformations, with an alpha of 0.05. Approximately 800 cases in each group would be required to detect a twofold risk of relatively common malformations, and thousands of cases would be required to detect rare defects.
In this cohort of women exposed to trazodone or nefazodone during pregnancy, all of whom took these antidepressants during the first trimester, the results do not suggest a risk for major malformations above the baseline rate of 1% to 3%. This evidence-based information can help women and their health professionals when they are deciding whether to treat depression with these particular drugs during pregnancy. Résumé : Une étude multicentrique prospective contrôlée pour déterminer l'innocuité de l'utilisation de la trazodone et de la néfazodone durant la grossesse Objectifs : La trazodone et la néfazodone sont des antidépresseurs de classe phenylpiperazine. À l'heure actuelle, il n'y a pas d'études adéquates bien contrôlées sur l'innocuité de ces médicaments pour le foetus. Notre principal objectif était de déterminer si l'utilisation de la trazodone ou de la néfa-zodone durant la grossesse est associée à un risque accru de malformations graves. Les résultats secondaires d'intérêt comprenaient les taux d'avortement spontané et thérapeutique, les taux d'accouchement prématuré et le poids à la naissance.
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Méthodes : Les femmes enceintes de 5 centres qui avaient été exposées à ces médicaments (n = 147) ont été inscrites à l'étude pendant leur premier trimestre. Nous avons comparé ces femmes avec 2 groupes de femmes qui prenaient soit un autre antidépresseur (n = 147), soit des médicaments non té-ratogènes (n = 147). Toutes les femmes ont fait l'objet d'un suivi après l'accouchement pour évaluer l'issue de la grossesse et la santé du bébé.
Résultats : Nous avons effectué 147 suivis. Il y a eu 121 (82,4 %) naissances vivantes, 20 (13,6 %) avortements spontanés et 6 (4 %) avortements thérapeutiques. Parmi les naissances vivantes, il y avait 2 (1,6 %) malformations importantes. Dans tous les cas, l'exposition aux médicaments a eu lieu durant le premier trimestre, et 52 (35 %) femmes ont utilisé ces médicaments durant toute la grossesse. L'âge gestationnel moyen à la naissance était 38 semaines (ET 4,2), et le poids moyen à la naissance était 3 306,34 g (ET 655). Nous n'avons pas constaté de différences statistiquement significatives entre les 3 groupes pour tous les résultats d'intérêt que nous avons examinés. De l'échantillon, 58 femmes ont été exposées à la trazodone et 89 l'ont été à la néfazodone. Conclusion : Nos résultats suggèrent que ces médicaments ne haussent pas les taux de malformations graves au-dessus du taux de base de 1 % à 3 %.
